Please provide your email address to receive an email when new articles are posted on . Moderate to severe angiographic vasospasm was detected more often in controls than in those given implants. At ...

February 1, 2012 (New Orleans, Louisiana) — In a randomized trial, treatment with clazosentan, a still-investigational endothelin receptor antagonist, reduced the risk of vasospasm after aneurysmal ...

February 18, 2011 (Los Angeles, California) — Results of a randomized, double-blind trial have shown no significant benefit of treatment with clazosentan, an investigational endothelin receptor ...

Clazosentan—a drug previously demonstrated to reduce angiographic vasospasm in patients with aneurysmal subarachnoid hemorrhage—had no significant effect on vasospasm-related morbidity and mortality ...

CLINICAL, 1 angiographic 2 and experimental observations 3 indicate that the larger arteries of the brain, like other arteries of equivalent size, are capable of active vasospasm that may have serious ...